Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2021-05-03 Board/Management Inform…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Resignation of Director & Withdrawal of AGM Resolution 1
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 4 May 2021 regarding the resignation of a director, Mr. David Segal, and the withdrawal of certain AGM resolutions related to his re-election and option grants. It includes details about the director's tenure and the impact on the upcoming Annual General Meeting. There is no financial data, no report attached or referenced as being published, and the content focuses on management changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2021-05-03 English
Notice of Annual General Meeting/Proxy Form 26 pages 670.7KB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting Explanatory Statement and Proxy Form' and details the agenda, resolutions, and voting procedures for the AGM scheduled on 31 May 2021. It includes items such as adoption of the Remuneration Report, re-election of directors, approval of option grants, and ratification of prior share issues. The document is a notice and explanatory statement for the AGM, not the actual Annual Report or financial statements. It is a preparatory document sent to shareholders to inform them about the meeting and solicit votes. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial and contains detailed meeting information, consistent with an AGM notice and explanatory statement.
2021-04-29 English
March 2021 Quarterly Activities Report & Appendix 4C 8 pages 347.7KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 28 April 2021, titled 'Avecho Quarterly Activities Report and Appendix 4C' for the quarter ended 31 March 2021. It includes detailed operational updates, capital raising information, clinical trial progress, and a quarterly cash flow report (Appendix 4C) with financial data for the quarter. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year, along with operational and corporate updates, aligns with the characteristics of an Interim / Quarterly Report. The document is not merely an announcement of a report but contains the actual quarterly financial statements and activities report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2021
2021-04-27 English
Avecho receives ethics approval for CBD human trial 2 pages 72.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 13 April 2021 from Avecho Biotechnology Limited. It announces that the company has received ethics approval to conduct a Phase I human clinical trial to characterize drug absorption from its enhanced cannabidiol product. The content focuses on the clinical trial approval, study design, manufacturing details, and future development plans. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about a clinical trial milestone rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or insider dealing. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant company development that does not fit into other specific categories like earnings release, capital update, or management information.
2021-04-12 English
Annual Report - 31 December 2020 58 pages 800.7KB
Annual Report Classification · 100% confidence The document is titled 'Annual Report - 31 December 2020' and contains detailed sections typical of an annual report, including a corporate directory, directors' report, auditor's independence declaration, consolidated financial statements, notes to the financial statements, directors' declaration, and independent auditor's report. It covers the full fiscal year ending 31 December 2020 and includes comprehensive financial data, operational review, changes in state of affairs, and future outlook. The length of the document (15,000 characters) and the detailed financial and operational content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2020
2021-03-25 English
Appendix 4G and Corporate Governance Statement 25 pages 639.7KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a form used by Australian listed entities to confirm compliance with corporate governance disclosure requirements. The document includes a detailed checklist of governance principles and recommendations, indicating whether the entity has followed them and where disclosures can be found (e.g., in the corporate governance statement or on the website). It explicitly states that Appendix 4G is not a substitute for the corporate governance statement but serves as a verification tool for compliance with Listing Rule 4.10.3. The document does not contain financial statements or management discussion but is a regulatory filing related to governance disclosures. It is not an annual report, governance report itself, or a presentation but a regulatory compliance filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-03-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.